Navigation Links
High-Dose Chemo Fails Against Small Cell Lung Cancers
Date:4/9/2008

Tripled dose was ineffective and toxic, so strategy should be abandoned, study says

WEDNESDAY, April 9 (HealthDay News) -- High-intensity chemotherapy does not improve the survival rate of patients with small cell lung cancer (SCLC), a new Swiss study concludes.

Testing on 140 patients in a randomized trial showed no statistically significant differences in survival rate or tumor size between groups receiving either standard or high doses of chemo over a three-year period. The findings were published online April 8 in the Journal of the National Cancer Institute.

Researchers thought upping the amount of chemotherapy might help the patients live longer because laboratory data had suggested that higher doses kill SCLC cells resistant to standard doses.

"The approach explored in the present trial succeeded in raising the peak dose, total dose and dose intensity of (the chemotherapy drugs) by threefold but has clearly been ineffective and highly toxic," the authors wrote. "As a result, this strategy should be abandoned."

SCLC accounts for almost 13 percent of lung cancer cases in the United States. While many patients initially respond to chemotherapy, most suffer disease recurrence relatively quickly.

The study, lead by Dr. Serge Leyvraz of the University Hospital in Lausanne, Switzerland, compared high-dose and standard-dose chemotherapy using the drug agents: ifosfamide, carboplatin and etoposide (ICE).

The survival rates in the group were similar: 18 percent of the high-dose patients were alive after three years, 19 percent of standard-dose patients survived. Tumor shrinkage was also similar in the two groups: 78 percent among the high-dose recipients and 68 percent in the standard-dose arm.

More information

The National Cancer Institute has more about lung cancer.



-- Kevin McKeever



SOURCE: Journal of the National Cancer Institute, news release, April 8, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. High-dose chemo and stem cell transplant shows little or no survival benefit for breast cancer
2. High-Dose Chemo Provides Little Benefit to Breast Cancer Patients
3. High-Dose Chemo Helps Beat Rare Brain Cancer
4. Chemotherapy may be culprit for fatigue in breast cancer survivors
5. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
6. To evade chemotherapy, some cancer cells mimic stem cells
7. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
8. PET scans can accurately detect a breast tumors response to chemotherapy
9. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
10. New Software Program Helps Breast Cancer Survivors and Patients Fight Chemofog
11. Medicare modernization act did not change chemotherapy as feared
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... The Behavioral Health Center of ... the organization as a top behavioral service provider in the country. The award ... staff satisfaction and qualifications, and consumer satisfaction. These areas are measured via a ...
(Date:12/6/2016)... ... 2016 , ... Gateway Analytical, one of the world’s most ... sizing services for USP 788 and 789 particulate standards compliance. The new service ... to the needs of pharmaceutical and medical device manufacturers, who are required to ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... when SevenPoint2 released the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder ... one of the world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water ...
(Date:12/6/2016)... ... December 06, 2016 , ... Specialty Technical Publishers (STP) ... Audit Protocol Consortium (IAPC) EHS audit protocol for Great Britain . Leading ... of their EHS regulatory obligations and rapidly collect, share, archive, and export audit ...
(Date:12/6/2016)... ... 06, 2016 , ... U.S. Security Associates (USA) was named ... their industry leading training methods that engage their associates and link their achievements ... elite in employer-sponsored training and development programs. , “The 2017 Training Top 125 ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... and BOCA RATON, Fla. , ... for the Commercialization of Public Research (the ... a funding agreement SegAna, LLC, an ... University of Central Florida. The Florida Institute supports ... bridges early funding gaps for companies spinning out ...
(Date:12/5/2016)... , Dec. 5, 2016  Breckenridge Pharmaceutical, Inc. ... multi-product marketing agreement with development and manufacturing partner ... Under the terms of this agreement, Breckenridge will ... in the United States . ... tentatively-approved ANDA. The products cover a wide range ...
(Date:12/5/2016)... , Dec. 5, 2016  Sharn Anesthesia Inc. ... anesthesia sales and distribution partner for Salter Labs.  The ... the Year in recognition of outstanding sales performance. ... for respiratory and anesthesia care, including the market gold ... also the master distributor of the Parker Flex-Tip® Endotracheal ...
Breaking Medicine Technology: